Article
CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches.
Clinical pharmacology and therapeutics - 1 Oct 2026
Stone Rachael M, Hoffecker Glenda, Schultz April, Davis Brittney H, Bargal Salma A, Beitelshees Amber L, El Rouby Nihal, Norris Madeline, Rodriguez Kevin J, Limdi Nita, Cavallari Larisa H, Lee Craig R
Abstract excerpt
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no-function alleles. While CYP2C19-guided DAPT is well-established for some cardiovascular indications, its use in neurovascular settings has remained limited until...
Read the complete abstract on PubMedTopics
- Cytochrome P-450 CYP2C19
- Humans
- Clopidogrel
- Platelet Aggregation Inhibitors
- Pharmacogenomic Testing